GlassScriptPhysician profile
Luke Eastburg
NPI 1649626508
$559.92
in general payments reported to CMS, 2019-2025
12 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $215 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $190.69 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $60.47 | 2025 | Keytruda |
| Agios Pharmaceuticals, INC. | $56.77 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $48.57 | 2025 | Iclusig, Vpriv |
| Celgene Corporation | $41.10 | 2024-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $33.98 | 2024-2025 | |
| Eisai INC. | $28.50 | 2024 | |
| Incyte Corporation | $26.28 | 2025 | Jakafi |
| Glaxosmithkline, LLC. | $24.04 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $18.46 | 2025 | Darzalex, Tecvayli |
| Genentech USA, INC. | $16.79 | 2025 | Polivy |
| Abbvie INC. | $14.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Eastburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.